DK0835447T3 - Peptider og sammensætninger, der modulerer apoptose - Google Patents

Peptider og sammensætninger, der modulerer apoptose

Info

Publication number
DK0835447T3
DK0835447T3 DK96913307T DK96913307T DK0835447T3 DK 0835447 T3 DK0835447 T3 DK 0835447T3 DK 96913307 T DK96913307 T DK 96913307T DK 96913307 T DK96913307 T DK 96913307T DK 0835447 T3 DK0835447 T3 DK 0835447T3
Authority
DK
Denmark
Prior art keywords
compositions
domain
peptides
bak
directed
Prior art date
Application number
DK96913307T
Other languages
English (en)
Inventor
Robert J Lutz
Thomas D Chittenden
Original Assignee
Apoptosis Technology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apoptosis Technology Inc filed Critical Apoptosis Technology Inc
Application granted granted Critical
Publication of DK0835447T3 publication Critical patent/DK0835447T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK96913307T 1995-05-12 1996-05-06 Peptider og sammensætninger, der modulerer apoptose DK0835447T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/440,391 US5656725A (en) 1995-05-12 1995-05-12 Peptides and compositions which modulate apoptosis

Publications (1)

Publication Number Publication Date
DK0835447T3 true DK0835447T3 (da) 2006-11-20

Family

ID=23748576

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96913307T DK0835447T3 (da) 1995-05-12 1996-05-06 Peptider og sammensætninger, der modulerer apoptose

Country Status (10)

Country Link
US (3) US5656725A (da)
EP (1) EP0835447B1 (da)
JP (1) JPH11506907A (da)
AT (1) ATE333645T1 (da)
CA (1) CA2220753C (da)
DE (1) DE69636365T2 (da)
DK (1) DK0835447T3 (da)
ES (1) ES2268704T3 (da)
PT (1) PT835447E (da)
WO (1) WO1996035951A1 (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0731636B1 (en) 1993-11-30 2006-01-11 Tanox, Inc. Cdn apoptosis-modulating proteins, dna encoding the proteins and methods of use thereof
US6221615B1 (en) * 1995-05-12 2001-04-24 Apoptosis Technology, Inc. Peptides and compositions which modulate apoptosis
US6441135B1 (en) * 1997-03-20 2002-08-27 Tanox, Inc. Bak binding protein, DNA encoding the protein, and methods of use thereof
WO1998058541A1 (en) * 1997-06-24 1998-12-30 Dana-Farber Cancer Institute, Inc. Modulation of apoptosis
WO1999015179A1 (en) * 1997-09-25 1999-04-01 Regents Of The University Of Minnesota Methods of limiting apoptosis of cells
WO1999016787A1 (en) * 1997-09-26 1999-04-08 Washington University Cell death agonists
US6165732A (en) * 1997-10-14 2000-12-26 Washington University Method for identifying apoptosis modulating compounds
US6720311B2 (en) 1997-12-18 2004-04-13 David Tsai Polypeptide for the treatment of cancer and a method for preparation thereof
US7238662B2 (en) * 1997-12-18 2007-07-03 Ambryx Biotechnology, Inc. Alpha 2HS glycoprotein for treatment of cancer and a method for preparation thereof
US6737402B2 (en) 1997-12-18 2004-05-18 David Tsai Method of preparing fetuin to induce apoptosis
US6645490B2 (en) * 1998-03-02 2003-11-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities
US6190912B1 (en) * 1998-03-31 2001-02-20 Thomas Jefferson University Blk genes and uses thereof in apoptosis
CA2329868A1 (en) * 1998-05-18 1999-11-25 Apoptosis Technology, Inc. Compounds, screening methods, and uses involving anti-apoptotic genes and gene products
US6218511B1 (en) 1998-05-18 2001-04-17 Apoptosis Technology, Inc. Anti-apoptotic genes of human cytomegalovirus (HCMV) and their use
AU5761200A (en) * 1999-06-25 2001-01-31 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Bh3 modified peptides
US20040157327A1 (en) * 1999-10-22 2004-08-12 Wyeth Pablo, a polypeptide that interacts with BCL-XL, and uses related thereto
BR0014961A (pt) 1999-10-22 2002-07-02 Wyeth Corp Pablo, um polipeptìdeo que interage com bcl-xl, e utilização relacionada ao mesmo
AU2001253758A1 (en) * 2000-04-24 2001-11-07 Yale University DNA and protein binding miniature proteins
US7495070B2 (en) * 2000-04-24 2009-02-24 Yale University Protein binding miniature proteins
US20030044413A1 (en) * 2000-08-15 2003-03-06 Regents Of The University Of Minnesota Methods of limiting apoptosis of cells
US20040043949A1 (en) * 2002-08-30 2004-03-04 Christopher Richardson Therapeutic system targeting pathogen proteases and uses thereof
JP2006510740A (ja) * 2002-11-07 2006-03-30 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 出血と関連した神経系障害を治療する方法
US20060204481A1 (en) * 2003-04-02 2006-09-14 Steer Clifford J Methods of promoting cell viability
US20080138847A1 (en) * 2004-09-23 2008-06-12 Yigong Shi Bcl-2 family member and BH-3 only proteins for use in development of peptidomimetics
EP1871385A1 (en) * 2005-02-10 2008-01-02 Regents Of The University Of Minnesota Methods for treating visual disorders
EP2023946A1 (en) * 2006-05-08 2009-02-18 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of gliotoxin
US7790184B2 (en) * 2006-08-01 2010-09-07 Washington University In St. Louis Cytochrome c synthesis inhibitors
US20100273722A1 (en) * 2007-08-06 2010-10-28 Yale University Modified miniature proteins
WO2012080548A1 (es) * 2010-12-17 2012-06-21 Consejo Superior De Investigaciones Científicas (Csic) Mutante de bak, método asociado para la identificación de sustancias moduladoras de bak y péptido inhibidor de la actividad bak

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015568A (en) * 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
US5202429A (en) * 1986-07-09 1993-04-13 The Wistar Institute DNA molecules having human BCL-2 gene sequences
US5283173A (en) * 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US6221615B1 (en) * 1995-05-12 2001-04-24 Apoptosis Technology, Inc. Peptides and compositions which modulate apoptosis

Also Published As

Publication number Publication date
JPH11506907A (ja) 1999-06-22
DE69636365T2 (de) 2007-08-02
US5863795A (en) 1999-01-26
EP0835447B1 (en) 2006-07-19
ATE333645T1 (de) 2006-08-15
EP0835447A4 (en) 1999-06-02
PT835447E (pt) 2006-12-29
US20090081705A1 (en) 2009-03-26
EP0835447A1 (en) 1998-04-15
CA2220753A1 (en) 1996-11-14
CA2220753C (en) 2010-12-21
US5656725A (en) 1997-08-12
DE69636365D1 (de) 2006-08-31
ES2268704T3 (es) 2007-03-16
WO1996035951A1 (en) 1996-11-14

Similar Documents

Publication Publication Date Title
DK0835447T3 (da) Peptider og sammensætninger, der modulerer apoptose
EA200000449A1 (ru) Модифицированные витамины к-зависимые полипептиды
ATE183196T1 (de) Peptidinhibitoren von fibronectin und verwandten kollagen-bindenden proteinen
NO20061455L (no) 2,6 dioksopiperidin samt farmasoytiske preparater som inneholder disse
ES2175083T3 (es) Moduladores de la agregacion de amiloides.
NZ500282A (en) Use of thienyl, furyl, pyrrolyl and biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
ATE217754T1 (de) Verwendung von aerogelen in der landwirtschaft
ATE235510T1 (de) Integrinbindendes peptid und dessen verwendung
DE69818450D1 (de) Im wesentlichen reines zonulin als physiologischer modulator von "tight junctions" bei säugern
ES8604265A1 (es) Un metodo para preparar un peptido o una sal no toxica del mismo.
ATE476495T1 (de) Bazillus thuringiensis und dessen insektizide proteine
DE69738930D1 (de) Methoden zur modulation der melaninsynthese
BR9913190A (pt) Modulação de proteìnas quinase de linhagemmúltipla
BR0009804A (pt) Peptìdeos moduladores de adesão e seus usos
ATE222492T1 (de) Verwendung von indolderivaten als 5ht1-agonisten
DE60327936D1 (de) Modulatoren von ship-1
DK0984983T3 (da) Modulatorer af intracellulære inflammations-, celledöds- og celleoverlevelsesforlöb indeholdende et CARD- og et kinasedomæne
DE69510545T2 (de) Cck oder gastrin modulierende 5-heterocyclicyl-1,5-benzodiazepine
ATE272315T1 (de) Modulierung von calciumkanälen
DE60132301D1 (de) Verwendung der extrazellulären Domäne von TRADE Molekülen in Medikamenten zur Behandlung von Neoplasie
BR0014961A (pt) Pablo, um polipeptìdeo que interage com bcl-xl, e utilização relacionada ao mesmo
DE68923613T2 (de) Superoxid-dismutaseanaloge mit neuen bindeeigenschaften.
SE9802538D0 (sv) New pharmaceutically active compounds
DE69518319D1 (de) Verwendung von oberflächenaktiven substanzen zur stabilisierung von peptiden und proteinen zur radiopharmazeutischen verwendung
FI960839A (fi) Uusia tripeptidejä, jotka ovat käyttökelpoisia immuuni- ja CNS-terapiassa